Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


29.06.2020

2 AJR Am J Roentgenol
1 Am J Clin Oncol
2 BJU Int
4 BMC Cancer
1 BMC Urol
1 Br J Cancer
1 Br J Radiol
1 Cancer
2 Clin Cancer Res
1 Eur J Radiol
1 Eur Urol
3 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Clin Oncol
9 J Urol
4 JAMA
1 N Engl J Med
1 Nat Rev Urol
2 Oncogene
1 Oncol Rep
1 Oncology
1 PLoS One
2 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MARCUS C, Butler P, Bagrodia A, Cole S, et al
    Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    AJR Am J Roentgenol. 2020 Jun 17:1-10. doi: 10.2214/AJR.19.22404.
    PubMed         Abstract available

  2. WANG Y, Chow DZ, Ebert E, Tajmir S, et al
    Utility of (18)F-Fluciclovine PET/CT for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 ng/mL) or Very Low (< 0.3 ng/mL) Prostate-Specific Antigen Levels.
    AJR Am J Roentgenol. 2020 Jun 22:1-5. doi: 10.2214/AJR.19.22180.
    PubMed         Abstract available


    Am J Clin Oncol

  3. LEHRER S, Rheinstein PH
    Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.
    Am J Clin Oncol. 2020 Jun 19. doi: 10.1097/COC.0000000000000727.
    PubMed         Abstract available


    BJU Int

  4. MAYOR N, Sathianathen NJ, Buteau J, Koschel S, et al
    PSMA Theranostics in advanced prostate cancer: an evolving option.
    BJU Int. 2020 Jun 19. doi: 10.1111/bju.15143.
    PubMed         Abstract available

  5. ANTON A, Kamel Hasan O, Ballok Z, Bowden P, et al
    Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer.
    BJU Int. 2020 Jun 24. doi: 10.1111/bju.15151.
    PubMed         Abstract available


    BMC Cancer

  6. CHOI JB, Myong JP, Lee Y, Kim I, et al
    Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference.
    BMC Cancer. 2020;20:589.
    PubMed         Abstract available

  7. MEHDI A, Cheishvili D, Arakelian A, Bismar TA, et al
    DNA methylation signatures of Prostate Cancer in peripheral T-cells.
    BMC Cancer. 2020;20:588.
    PubMed         Abstract available

  8. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed         Abstract available

  9. BOU-DARGHAM MJ, Sha L, Sang QA, Zhang J, et al
    Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    BMC Cancer. 2020;20:572.
    PubMed         Abstract available


    BMC Urol

  10. SRINIVAS S, Mohamed AF, Appukkuttan S, Botteman M, et al
    Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
    BMC Urol. 2020;20:73.
    PubMed         Abstract available


    Br J Cancer

  11. LI L, Hobson L, Perry L, Clark B, et al
    Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
    Br J Cancer. 2020 Jun 25. pii: 10.1038/s41416-020-0951.
    PubMed         Abstract available


    Br J Radiol

  12. ASHTON J, Bristow R
    Bad neighbours: hypoxia and genomic instability in prostate cancer.
    Br J Radiol. 2020 Jun 18:20200087. doi: 10.1259/bjr.20200087.
    PubMed         Abstract available


    Cancer

  13. ITO K, Kobayashi M, Komiyama M, Naito S, et al
    Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Cancer. 2020 Jun 23. doi: 10.1002/cncr.33034.
    PubMed         Abstract available


    Clin Cancer Res

  14. PALANISAMY N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, et al
    The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.
    Clin Cancer Res. 2020 Jun 23. pii: 1078-0432.CCR-20-0479.
    PubMed         Abstract available

  15. PEREZ-RUIXO C, Ackaert O, Ouellet D, Chien C, et al
    Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-1041.
    PubMed         Abstract available


    Eur J Radiol

  16. WEI CG, Chen T, Zhang YY, Pan P, et al
    Erratum to "Biparameteric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels" [Eur. J. Radiol. 127 (2020) 108977].
    Eur J Radiol. 2020 Jun 21:109129. doi: 10.1016/j.ejrad.2020.109129.
    PubMed        


    Eur Urol

  17. MUKHERJI D, Omlin A, Pezaro C
    Living Longer and Better with Advanced Prostate Cancer.
    Eur Urol. 2020 Jun 15. pii: S0302-2838(20)30360.
    PubMed        


    Int J Radiat Oncol Biol Phys

  18. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
    Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
    PubMed         Abstract available

  19. ROY S, Grimes S, Eapen L, Spratt DE, et al
    Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
    PubMed         Abstract available

  20. MITIN T, Choudhury A
    Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
    Int J Radiat Oncol Biol Phys. 2020;107:609-612.
    PubMed        


    Int J Urol

  21. NAKAI Y, Tanaka N, Asakawa I, Anai S, et al
    Biochemical control of the combination of cyclooxygenase-2 inhibitor and (125) I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14294.
    PubMed         Abstract available


    J Clin Oncol

  22. XIE W, Regan MM, Buyse M, Halabi S, et al
    Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    J Clin Oncol. 2020 Jun 18:JCO1903114. doi: 10.1200/JCO.19.03114.
    PubMed         Abstract available


    J Urol

  23. TANEJA SS
    Re: Validation of a Subclassification for High-Risk Prostate Cancer in a Prospective Cohort.
    J Urol. 2020 Jun 26:101097JU0000000000001176. doi: 10.1097/JU.0000000000001176.
    PubMed        

  24. TANEJA SS
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-Based, Diagnostic Study.
    J Urol. 2020 Jun 26:101097JU000000000000117602.
    PubMed        

  25. RESNICK MJ
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Jun 26:101097JU0000000000001171. doi: 10.1097/JU.0000000000001171.
    PubMed        

  26. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Inter-reader Agreement in Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2020 Jun 18:101097JU0000000000001200. doi: 10.1097/JU.0000000000001200.
    PubMed         Abstract available

  27. TANEJA SS
    Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    J Urol. 2020 Jun 26:101097JU000000000000117601.
    PubMed        

  28. ATALA A
    Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-kappaB Activation.
    J Urol. 2020 Jun 18:101097JU0000000000001179. doi: 10.1097/JU.0000000000001179.
    PubMed        

  29. MOSCHINI M, Rozet F
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed        

  30. KILPELAINEN T, Lahdensuo K, Rannikko A
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed        

  31. REISZ PA, Laviana AA, Zhao Z, Huang LC, et al
    Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study.
    J Urol. 2020 Jun 22:101097JU0000000000001198. doi: 10.1097/JU.0000000000001198.
    PubMed         Abstract available


    JAMA

  32. PARSONS JK, Pierce JP, Marshall JR
    Vegetable Consumption and Progression of Prostate Cancer-Reply.
    JAMA. 2020;323:2530.
    PubMed        

  33. CSIZMADI I, Lin PH, Freedland SJ
    Vegetable Consumption and Progression of Prostate Cancer.
    JAMA. 2020;323:2529-2530.
    PubMed        

  34. SLOMSKI A
    Prostate Cancer Drug Degarelix Rapidly Treats Pedophilic Disorder.
    JAMA. 2020;323:2453.
    PubMed        

  35. KERLEY CP
    Vegetable Consumption and Progression of Prostate Cancer.
    JAMA. 2020;323:2528-2529.
    PubMed        


    N Engl J Med

  36. SHOAG JE, Nyame YA, Gulati R, Etzioni R, et al
    Reconsidering the Trade-offs of Prostate Cancer Screening.
    N Engl J Med. 2020;382:2465-2468.
    PubMed        


    Nat Rev Urol

  37. OMAR MI, Roobol MJ, Ribal MJ, Abbott T, et al
    Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
    Nat Rev Urol. 2020 Jun 25. pii: 10.1038/s41585-020-0355.
    PubMed         Abstract available


    Oncogene

  38. KOHVAKKA A, Sattari M, Shcherban A, Annala M, et al
    AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.
    Oncogene. 2020 Jun 17. pii: 10.1038/s41388-020-1365.
    PubMed         Abstract available

  39. NOLLET EA, Cardo-Vila M, Ganguly SS, Tran JD, et al
    Androgen receptor-induced integrin alpha6beta1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
    Oncogene. 2020 Jun 21. pii: 10.1038/s41388-020-1370.
    PubMed         Abstract available


    Oncol Rep

  40. WANG Y, Pei X, Xu P, Tan Z, et al
    E2F7, regulated by miR30c, inhibits apoptosis and promotes cell cycle of prostate cancer cells.
    Oncol Rep. 2020 Jun 24. doi: 10.3892/or.2020.7659.
    PubMed         Abstract available


    Oncology

  41. DI LORENZO G, Buonerba L, Ingenito C, Crocetto F, et al
    Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy.
    Oncology. 2020 Jun 22:1-5. doi: 10.1159/000509434.
    PubMed         Abstract available


    PLoS One

  42. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed         Abstract available


    Prostate

  43. MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
    Can ultrasound irradiation be a therapeutic option for prostate cancer?
    Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
    PubMed         Abstract available

  44. CHEN Y, Li X, Mamouni K, Yang Y, et al
    Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
    Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: